Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes

Leukemia

Volumn 23, Issue 1, 2009, Pages 182-184

  Kuendgen, A ^a   Gattermann, N ^a   Germing, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RISK; CYTOGENETICS; DISEASE COURSE; DISEASE REGISTRY; GARCIA MANERO SCORING SYSTEM; GENETIC RISK; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LETTER; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

EID: 58249096414     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.153     Document Type: Letter

References (8)

1. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2007; 22: 538-543.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
4. Steidl C, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kündgen A et al. Growing evidence for an underestimation of poor- risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes. Clinical Leukemia 2008; 1: 353-356.
5. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
6. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C et al. Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.
7. Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 2008; 32: 33-37.
8. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L et al Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008; 22: 313-322.